Completed × NIH × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Clear all Veliparib and Temozolomide in Treating Patients With Acute Leukemia
Phase 1 Completed
66 enrolled
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Phase 3 Completed
1,895 enrolled 16 charts
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase 2 Completed
3 enrolled 8 charts
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
16 enrolled 8 charts
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Phase 1 Completed
6 enrolled 16 charts
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Phase 2 Completed
93 enrolled 12 charts
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
Phase 1 Completed
89 enrolled
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Phase 2 Completed
42 enrolled 10 charts
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
14 enrolled 7 charts
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
Immunotoxin in Treating Patients With Leukemia or Lymphoma
Phase 1 Completed
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1 Completed
15 enrolled
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
12 enrolled
Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
Phase 2 Completed
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
Phase 3 Completed
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
Monoclonal Antibody Therapy in Treating Patients With Leukemia
Phase 1/2 Completed
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
Phase 1 Completed
28 enrolled
Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma
Phase 1 Completed
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
Phase 1 Completed
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed
Perillyl Alcohol in Treating Patients With Refractory Cancer
Phase 1 Completed
25 enrolled
Penclomedine in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
Phase 1 Completed
40 enrolled
BMS-247550 in Treating Patients With Advanced Cancers
Phase 1 Completed
54 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
3 enrolled
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Completed
35 enrolled
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
60 enrolled
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
45 enrolled
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
72 enrolled
506U78 in Treating Patients With Lymphoma
Phase 2 Completed
74 enrolled
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
Phase 1 Completed
108 enrolled
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
18 enrolled
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
Phase 1 Completed
70 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled